The Arthritis Advocate: Vol.7 – Medication access: Approved does not mean accessible

What does it really mean to have “access” to an arthritis medication?

What does it really mean to have “access” to an arthritis medication?

It's Global Biosimilars Week. Biosimilars are delivering substantial savings—and patients have a stake in protecting that progress.

A recent article published in The Daily Record highlighted how big pharma's patent games are costing patients. Read the full article here.

Once a month, the Crohn's & Colitis Foundation (US) brings all staff together (from all the departments at the Foundation) to share information, resources, and updates.

In this episode of Arthritis Consumer Experts' Arthritis At Home, host Cheryl Koehn speaks with Laura Wingate, Chief Education, Support, and Advocacy Officer of the Crohn’s and Colitis Foundation of the USA, about the Patients and patents campaign.

This webinar will help you understand patents clearly as well as encourage patients and caregivers to promote more timely availability of generics and biosimilars.

In this episode of Arthritis Consumer Experts' Arthritis At Home, host Cheryl Koehn speaks with Deidre Mackechnie, Executive Officer of the Australian Patient Advocacy Alliance, about her organization’s partnering with the Patients and patents campaign.

A recent article published on BioSpace summarizes an analysis conducted by Sean Tu of the University of Alabama School of Law. Tu's work cites multiple examples of pharmas using what the authors term serial litigation to stave off would-be competitors for years, allowing them to keep prices high.

ACE submitted an Op-Ed to the Globe and Mail, Canada’s national newspaper of record in response to an article focused on whether Canada’s drug pricing policies discourage pharmaceutical companies from launching innovative therapies.

This report from the International Generic and Biosimilar Medicines Association looks at the various strategies...